Effects of bisoprolol in combination with trimetazidine on the treatment of heart failure and concomitant chronic obstructive pulmonary disease
| Autor: | Yuanyuan Ke, Minxiong Li, Yongpeng Huang, Dingli Xu, Zenglong Wu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Cardiac function curve
Bisoprolol Fumarate medicine.medical_specialty Trimetazidine Diastole Heart failure 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Bisoprolol COPD business.industry Chronic obstructive pulmonary disease General Medicine medicine.disease respiratory tract diseases Concomitant Cardiology Original Article business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Pakistan Journal of Medical Sciences |
| ISSN: | 1681-715X 1682-024X |
| Popis: | Objective: To evaluate the effects of bisoprolol combined with trimetazidine on the treatment of heart failure patients having concomitant chronic obstructive pulmonary disease (COPD); in comparison with control group treated with standard therapy only. Methods: A total of 120 heart failure patients having concomitant COPD were selected and randomly divided into a control group and a treatment group according to different treatment methods (n=60). The control group was given continuous low flow oxygen inhalation and inotropic agents, and their cardiac stress was also reduced. The treatment group was treated with bisoprolol fumarate and trimetazidine in addition to treatment for COPD. For all patients, blood gas analysis and parameters reflecting cardiac function were measured respectively before and after treatment. The respiratory symptoms (cough, sputum, polypnea, gasp, dyspnea), limitation of motion (daily life, household duties, entertainment, sports), disease impacts (social contact, emotion, anxiety) and St. George’s Respiratory Questionnaire (SGRQ) total scores were observed using SGRQ. Results: The oxygen partial pressure (PaO2) and partial pressure of carbon dioxide (PaCO2) of the treatment group after treatment were significantly different from those before treatment. After treatment, peak E, E/A and IVEF were increased by 41%, 44% and 16% respectively, but peak A, LVPWT/mm and IVST/mm were significantly reduced. The differences in the respiratory symptoms, limitation of motion, disease impacts and SGRQ total scores were statistically significant compared with those before treatment (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|